AKT1 and neoplasm: We examined whether the PI3K/AKT pathway plays an important role in the maintenance of the CSC-like phenotype of the ex vivo EGFP+ hypoxic tumor cells using LY294002, a specific PI3K inhibitor, to suppress AKT activation (Additional file 2, pannel B).